Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy

被引:14
|
作者
Bedke, Jens [1 ]
Chun, Felix K-H [3 ]
Merseburger, Axel [4 ]
Scharpf, Marcus [2 ]
Kasprzyk, Kathrin [1 ]
Schilling, David [1 ]
Sievert, Karl-Dietrich [1 ]
Stenzl, Arnulf [1 ]
Kruck, Stephan [1 ]
机构
[1] Univ Tubingen, Dept Urol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[4] Hannover Med Sch, Dept Urol & Urooncol, Hannover, Germany
关键词
renal cell cancer; systemic inflammation; biomarkers; CRP; WBC; threshold; predictive accuracy; CANCER-SPECIFIC SURVIVAL; VALIDATION; BIOMARKER; MORTALITY; IMPACT; MODEL;
D O I
10.1111/j.1464-410X.2012.11642.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To re-evaluate the prognostic and predictive significance of the preoperative white blood cell (WBC) count and C-reactive protein (CRP) that independently predicts patient prognosis and to determine optimal threshold values for CRP. PATIENTS AND METHODS From 1996 to 2005, 327 patients with surgery for clear cell renal cell carcinoma were retrospectively evaluated. Cox proportional hazard models were used, adjusted for the effects of tumour stage, size, Fuhrman grade and Karnofsky index, to evaluate the prognostic significance of WBC count and CRP and to identify threshold values. Identified thresholds were correlated with clinicopathological parameters and used to estimate cancer-specific survival. To prove any additional predictive accuracy of the identified threshold it was compared with a clinicopathological base model using the Harrell concordance index (c-index). RESULTS In univariable analyses WBC count was a significant prognostic marker at a concentration of 9.5/mu L (hazard ratio [HR] 1.83) and 11.0/mu L (HR 2.09) and supported CRP values of 0.25 mg/dL (HR 6.47, P < 0.001) and 0.5 mg/dL (HR 7.15, P < 0.001) as potential threshold values. If adjusted by the multivariable models WBC count showed no clear breakpoint, but a CRP value of 0.25 mg/dL (HR 2.80, P = 0.027) proved to be optimal. Reduced cancer-specific survival was proved for CRP 0.25 mg/dL (median 69.9 vs 92.3 months). Median follow-up was 57.5 months with 72 (22%) tumour-related deaths. The final model built by the addition of CRP 0.25 mg/dL did not improve predictive accuracy (c-index 0.877) compared with the clinicopathological base model (c-index 0.881) which included TNM stage, grading and Karnofsky index. CONCLUSIONS Multivariable analyses revealed that an optimal breakpoint of CRP at a value of 0.25 mg/dL was best to stratify patients at risk of cancer-specific mortality, but CRP 0.25 mg/dL added no additional information in the prediction model. Therefore we cannot recommend measuring CRP as the traditional parameters of TNM stage, grading and Karnofsky index are already of high predictive accuracy.
引用
收藏
页码:E771 / E777
页数:7
相关论文
共 50 条
  • [1] Prognostic Impact of Intratumoral C-Reactive Protein Expression in Patients with Clear Cell Renal Cell Carcinoma
    Can, Cavit
    Acikalin, Mustafa Fuat
    Ozen, Ata
    Dundar, Emine
    UROLOGIA INTERNATIONALIS, 2014, 92 (03) : 270 - 275
  • [2] Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
    Pilskog, Martin
    Beisland, Christian
    Akslen, Lars A.
    Bostad, Leif
    Haug, Ase
    Heinrich, Daniel
    Hjelle, Karin M.
    Straume, Oddbjorn
    BMC UROLOGY, 2017, 17
  • [3] Evaluation of increased preoperative serum high sensitive C-reactive protein and procalcitonin levels on grade and stage of clear cell renal cell carcinoma
    Hamidi, Nurullah
    Gokce, Mehmet Ilker
    Suer, Evren
    Baltaci, Sumer
    CLINICAL NEPHROLOGY, 2015, 83 (04) : 225 - 230
  • [4] Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein
    Jagdev, S. P. K.
    Gregory, W.
    Vasudev, N. S.
    Harnden, P.
    Sim, S.
    Thompson, D.
    Cartledge, J.
    Selby, P. J.
    Banks, R. E.
    BRITISH JOURNAL OF CANCER, 2010, 103 (11) : 1649 - 1656
  • [5] C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab
    Roussel, Eduard
    Kinget, Lisa
    Verbiest, Annelies
    Debruyne, Philip R.
    Baldewijns, Marcella
    Van Poppel, Hendrik
    Albersen, Maarten
    Beuselinck, Benoit
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (04) : 239.e17 - 239.e25
  • [6] Role of C-reactive protein as a biomarker for renal cell carcinoma
    Saito, Kazutaka
    Kihara, Kazunori
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (12) : 1979 - 1989
  • [7] Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Takagi, Toshio
    Kondo, Tsunenori
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    TARGETED ONCOLOGY, 2019, 14 (04) : 453 - 463
  • [8] Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma
    Nakayama, Takayuki
    Saito, Kazutaka
    Kumagai, Jiro
    Nakajima, Yutaka
    Kijima, Toshiki
    Yoshida, Soichiro
    Kihara, Kazunori
    Fujii, Yasuhisa
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : E1151 - E1158
  • [9] C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib
    Fujita, Tetsuo
    Iwamura, Masatsugu
    Ishii, Daisuke
    Tabata, Ken-ichi
    Matsumoto, Kazumasa
    Yoshida, Kazunari
    Baba, Shiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (10) : 908 - 913
  • [10] C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
    Noguchi, Go
    Nakaigawa, Noboru
    Umemoto, Susumu
    Kobayashi, Kota
    Shibata, Yosuke
    Tsutsumi, Sohgo
    Yasui, Masato
    Ohtake, Shinji
    Suzuki, Takahisa
    Osaka, Kimito
    Muraoka, Kentaro
    Hasumi, Hisashi
    Kondo, Keiichi
    Igarashi, Yuka
    Sasada, Tetsuro
    Kishida, Takeshi
    Yao, Masahiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 75 - 85